Key Points
- Takeda insider Andrew Stewart Plump sold 19,651 shares for approximately $363,347 under a pre-arranged Rule 10b5-1 plan, reducing his direct ownership by 6.99% to 261,656 shares.
- Takeda reported quarterly EPS of $0.47 and revenue of $7.50 billion, exceeding analyst estimates of $0.17 EPS and $7.13 billion in revenue.
- Analyst sentiment remains mixed, with two Buy ratings, one Hold, and one Sell; MarketBeat’s overall consensus rating is Hold.
Takeda Pharmaceutical Co. (NYSE:TAK - Get Free Report) insider Andrew Stewart Plump sold 19,651 shares of the firm's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $18.49, for a total transaction of $363,346.99. Following the completion of the transaction, the insider directly owned 261,656 shares in the company, valued at $4,838,019.44. This trade represents a 6.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Andrew Stewart Plump also recently made the following trade(s):
- On Monday, August 10th, Andrew Stewart Plump sold 165,393 shares of Takeda Pharmaceutical stock. The shares were sold at an average price of $17.10, for a total transaction of $2,828,220.30.
Takeda Pharmaceutical Trading Up 0.2%
NYSE:TAK opened at $18.17 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.90. The company has a market cap of $58.22 billion, a PE ratio of 53.44 and a beta of -0.08. The firm has a 50-day moving average of $16.79 and a 200-day moving average of $17.18.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.30. The business had revenue of $7.50 billion during the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. As a group, equities research analysts expect that Takeda Pharmaceutical Co. will post 1.54 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of equities research analysts recently commented on TAK shares. Weiss Ratings lowered Takeda Pharmaceutical from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Thursday, July 30th. Zacks Research upgraded shares of Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 4th. Finally, Wall Street Zen upgraded shares of Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a report on Saturday, July 18th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold".
Check Out Our Latest Stock Report on TAK
Hedge Funds Weigh In On Takeda Pharmaceutical
Several institutional investors have recently modified their holdings of the business. Private Trust Co. NA lifted its holdings in Takeda Pharmaceutical by 84.7% during the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company's stock worth $27,000 after acquiring an additional 783 shares during the period. Parkside Financial Bank & Trust grew its stake in Takeda Pharmaceutical by 192.2% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company's stock valued at $40,000 after purchasing an additional 1,684 shares during the period. SHP Wealth Management purchased a new stake in shares of Takeda Pharmaceutical during the 4th quarter valued at $42,000. Caitong International Asset Management Co. Ltd raised its stake in shares of Takeda Pharmaceutical by 313.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company's stock worth $48,000 after purchasing an additional 2,328 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its stake in shares of Takeda Pharmaceutical by 56.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company's stock worth $55,000 after purchasing an additional 1,292 shares during the period. 9.17% of the stock is owned by institutional investors.
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.
Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
